The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
9 Despite the promising preliminary results, significant research gaps remain regarding the use of GLP-1 RAs in IIH treatment
Side Effects Nausea or diarrhea, common side effects of semaglutide, can leave you feeling tired and drained
Findings from the semaglutide study Researchers undertook a detailed study involving HFpEF patients
Circulation 115:10901100 Schmieder R, Ott C, Linz P, Jumar A et al (2016) OS 1203 SGLT-2-inhibition with dapagliflozin reduces tissue sodium content